MaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability (NASDAQ:MXCT)
· seekingalpha.com
MaxCyte raises 2026 revenue outlook to at least $34.5 million and agrees to acquire Akron Bio, expected to generate $28 million in 2026 revenue.
Earnings Call Insights MaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability Nov 11, 2026, 6:02 AM ET MaxCyte, In...